MICHAEL TOLWIN: Open Payments
NPI 1497797427 · CULVER CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$916 in 63 payments from 8 companies in 2025. Trend: 2023 $1,848 · 2024 $1,589 · 2025 $916
Food & beverage: $916
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 31 | $321 |
| Alkermes, Inc. | 15 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $140 |
| Neurocrine BioSciences, Inc. | 6 | $106 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
Products named: INVEGA SUSTENNA, ARISTADA, CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, FANAPT.
Industry payments across CA — which companies pay providers there.
